Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G.

Arch Gen Psychiatry. 2002 Apr;59(4):337-45. Review.

PMID:
11926934
2.

Hyperglycemia and antipsychotic medications.

Haupt DW, Newcomer JW.

J Clin Psychiatry. 2001;62 Suppl 27:15-26; discussion 40-1. Review.

3.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
4.

Metabolic risk during antipsychotic treatment.

Newcomer JW.

Clin Ther. 2004 Dec;26(12):1936-46. Review.

PMID:
15823759
5.

Atypical antipsychotics and glucose homeostasis.

Bergman RN, Ader M.

J Clin Psychiatry. 2005 Apr;66(4):504-14. Review.

PMID:
15816794
6.

Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.

Newcomer JW.

J Clin Psychiatry. 2004;65 Suppl 18:36-46. Review.

7.

Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment.

Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM 3rd.

Ann Clin Psychiatry. 2001 Jun;13(2):103-13. Review.

PMID:
11534925
8.

Antipsychotic medication: effects on regulation of glucose and lipids.

Kato MM, Goodnick PJ.

Expert Opin Pharmacother. 2001 Oct;2(10):1571-82. Review.

PMID:
11825300
9.

Antipsychotics and metabolics in the post-CATIE era.

Meyer JM.

Curr Top Behav Neurosci. 2010;4:23-42. Review.

PMID:
21312396
10.

The comorbidity of diabetes mellitus and psychiatric disorders.

Medved V, Jovanović N, Knapić VP.

Psychiatr Danub. 2009 Dec;21(4):585-8. Review.

11.

Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes.

Oberweis B, Gragnoli C.

J Cell Physiol. 2012 Aug;227(8):3001-6. doi: 10.1002/jcp.24023. Review.

PMID:
22105468
12.

Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes.

Buse JB.

J Clin Psychiatry. 2002;63 Suppl 4:37-41. Review.

13.

[Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics].

De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J.

Encephale. 2007 Mar-Apr;33(2):197-202. French.

PMID:
17675915
14.

The metabolic effects of antipsychotic medications.

Newcomer JW, Haupt DW.

Can J Psychiatry. 2006 Jul;51(8):480-91. Review.

PMID:
16933585
15.

Differential metabolic effects of antipsychotic treatments.

Haupt DW.

Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S149-55. Epub 2006 Jul 25. Review.

PMID:
16872808
16.

Do antipsychotics increase diabetes risk in children and adolescents?

Galling B, Correll CU.

Expert Opin Drug Saf. 2015 Feb;14(2):219-41. doi: 10.1517/14740338.2015.979150. Epub 2014 Dec 5. Review.

PMID:
25480466
17.

Metabolic monitoring for patients treated with antipsychotic medications.

Cohn TA, Sernyak MJ.

Can J Psychiatry. 2006 Jul;51(8):492-501. Review.

PMID:
16933586
18.

Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.

Mayfield K, Siskind D, Winckel K, Russell AW, Kisely S, Smith G, Hollingworth S.

J Psychopharmacol. 2016 Mar;30(3):227-36. doi: 10.1177/0269881115625496. Epub 2016 Jan 22. Review.

PMID:
26801056
19.

[Schizophrenia, diabetes and new neuroleptics].

Ambresin G, Bryois Ch.

Praxis (Bern 1994). 2002 Dec 11;91(50):2181-92. Review. French.

PMID:
12520727
20.

The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.

Citrome LL.

Drugs Today (Barc). 2004 May;40(5):445-64. Review.

PMID:
15319799

Supplemental Content

Support Center